AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 355958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31386685 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive ironHand glove
Number of subjects: 91
Study 31386685 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ironHand glove
Number of subjects: 91
Study 31386685 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive and therapeutic ironHand use
Number of subjects: 91
Study 31386685 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic group
Number of subjects: 91
Study 31386685 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 29087373 — intervention group
Group type: EXPERIMENTAL
Intervention: IC/BST stimulation
Number of subjects: 7
Study 29087373 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 7
Study 29087373 — intervention group
Group type: EXPERIMENTAL
Intervention: ITP stimulation
Number of subjects: 7
Study 25157499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutribèn Pre
Number of subjects: 97
Study 25157499 — intervention group
Group type: COMPARATOR
Intervention: Fortified human milk (FHM)
Number of subjects: 97
Study 23623462 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on fresh frozen cadavers (FFCs), 10 repetitions of structured laparoscopic tasks
Number of subjects: 19
Study 23623462 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on fresh frozen cadavers (FFCs)
Number of subjects: 19
Study 23623462 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 19
Study 21729808 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion to maintain BG level between 110 mg/dL and 126 mg/dL during surgery
Number of subjects: 120
Study 21729808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no insulin therapy)
Number of subjects: 120
Study 19458605 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg once daily
Number of subjects: 32
Study 19458605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16317423 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive walking-like exercise (PWE) in quadriplegics
Number of subjects: 13
Study 14767445 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (0.016 mg/kg per IgE (IU/mL))
Number of subjects: 24
Study 14767445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11027921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (20 mg or 40 mg)
Number of subjects: 14
Study 11027921 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study 9327081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead exposure measures (blood lead levels at the time of SVRT testing)
Number of subjects: 284
Study 9327081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead exposure measures (recent and cumulative exposure measures)
Number of subjects: 284
Study 9327081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative exposure measures
Number of subjects: 284
Study 9327081 — intervention group
Group type: EXPERIMENTAL
Intervention: SVRT parameters (mean, median, truncated mean, and standard deviation)
Number of subjects: 284
Study 9327081 — intervention group
Group type: EXPERIMENTAL
Intervention: SVRT testing
Number of subjects: 284
Study 8471512 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 0
Study 8471512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 0
Study 3302148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 236
Study 3302148 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 236
Study 3302148 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 236
Study 29613883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 37
Study 29613883 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 37
Study 27209269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of renal replacement therapy (RRT) within 8 hours of diagnosis (n=112)
Number of subjects: 231
Study 27209269 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of renal replacement therapy (RRT) within 12 hours of stage 3 AKI or no initiation (n=119)
Number of subjects: 231
Study 27209269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of RRT
Number of subjects: 231
Study 27209269 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of RRT
Number of subjects: 231
Study 25189358 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16/18 AS04-adjuvanted vaccine
Number of subjects: 5752
Study 25189358 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 5752
Study 25189358 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 5752
Study 23768153 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management vocational rehabilitation (VR) service
Number of subjects: 18
Study 23768153 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 18
Study 19925273 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation (HR)
Number of subjects: 102
Study 19925273 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 102
Study 18054942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment (3 years)
Number of subjects: 61
Study 15630733 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice a week
Number of subjects: 40
Study 15630733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12021690 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 666
Study 12021690 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders
Number of subjects: 666
Study 10194223 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O2 breathing (26% O2-balance N2) during heavy exercise
Number of subjects: 6
Study 10194223 — intervention group
Group type: EXPERIMENTAL
Intervention: HeO2 breathing (26% O2-balance He) during heavy exercise
Number of subjects: 6
Study 8547380 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation Unit (GEU) for comprehensive geriatric assessment (CGA)
Number of subjects: 123
Study 2182255 — intervention group
Group type: EXPERIMENTAL
Intervention: AO dynamic hip screw
Number of subjects: 155
Study 2182255 — intervention group
Group type: COMPARATOR
Intervention: Jewett nail plate
Number of subjects: 155
Study 7373087 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 88
Study 7373087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 30651138 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily for 2 weeks
Number of subjects: 108
Study 30651138 — intervention group
Group type: COMPARATOR
Intervention: Placebo 200 mg once daily for 2 weeks
Number of subjects: 108
Study 30651138 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 108
Study 30989966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Culuan Decoction
Number of subjects: 90
Study 30989966 — intervention group
Group type: COMPARATOR
Intervention: Estradiol valerate, Clomiphene, and Progesterone (Control)
Number of subjects: 90
Study 28419834 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive condition
Number of subjects: 112
Study 28419834 — intervention group
Group type: EXPERIMENTAL
Intervention: Winners
Number of subjects: 112
Study 28419834 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 112
Study 28419834 — intervention group
Group type: COMPARATOR
Intervention: Non-competitive condition
Number of subjects: 112
Study 28419834 — intervention group
Group type: COMPARATOR
Intervention: Losers
Number of subjects: 112
Study 28419834 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 112
Study 26814106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve cryoanalgesia
Number of subjects: 71
Study 26814106 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia
Number of subjects: 71
Study 23014927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atrial natriuretic peptide (ANP) at 0.03 μg/kg/min
Number of subjects: 14
Study 23014927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at 0.3 μg/kg/min
Number of subjects: 14
Study 23014927 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 14
Study 21978409 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-oriented, personal recruitment approach
Number of subjects: 1319
Study 21978409 — intervention group
Group type: COMPARATOR
Intervention: Written invitations via general practitioners
Number of subjects: 1319
Study 21978409 — intervention group
Group type: COMPARATOR
Intervention: Health care professional referrals
Number of subjects: 1319
Study 18290862 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 233
Study 18290862 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 233
Study 18290862 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 233
Study 18290862 — intervention group
Group type: COMPARATOR
Intervention: IGlar
Number of subjects: 233
Study 18290862 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 and IGlar
Number of subjects: 233
Study 16796836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary transplantation of autologous BM-MNC
Number of subjects: 40
Study 16796836 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and heparin (Control)
Number of subjects: 40
Study 12697853 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin (30 mg daily for 2 years)
Number of subjects: 402
Study 12697853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 2 years)
Number of subjects: 402
Study 10955436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 162
Study 10955436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 162
Study 9117020 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐761 (200 mg)
Number of subjects: 9
Study 9117020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8436457 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted postoperative instructions (limited activities and soft food liquid diet for 7-10 days)
Number of subjects: 92
Study 8436457 — intervention group
Group type: COMPARATOR
Intervention: Nonrestricted postoperative instructions (return to activity and diet as tolerated)
Number of subjects: 92
Study 8436457 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 92
Study 3537093 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually polymerized grass (IPG) immunotherapy with an accelerated dosage schedule (24,000 PNU over 9 weekly visits)
Number of subjects: 44
Study 3537093 — intervention group
Group type: COMPARATOR
Intervention: Caramelized glucose histamine placebo
Number of subjects: 44
Study 3537093 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually polymerized grass (IPG) immunotherapy
Number of subjects: 44
Study 29197175 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-Diclofenac
Number of subjects: 0
Study 27733403 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D3/d supplementation for 20 weeks
Number of subjects: 119
Study 27733403 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg vitamin D3/d supplementation for 20 weeks
Number of subjects: 119
Study 27733403 — intervention group
Group type: COMPARATOR
Intervention: 0 μg vitamin D3/d (placebo) for 20 weeks
Number of subjects: 119
Study 24850229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg/day)
Number of subjects: 46
Study 24850229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24850229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received fluvoxamine (100 mg/day for the first 4 weeks, then 200 mg/day for the rest of the trial)
Number of subjects: 46
Study 22885123 — intervention group
Group type: COMPARATOR
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 37
Study 22885123 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification and intraocular lens implant (phaco/IOL)
Number of subjects: 37
Study 22885123 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco/IOL
Number of subjects: 37
Study 22885123 — intervention group
Group type: COMPARATOR
Intervention: LPI
Number of subjects: 37
Study 22885123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 20562469 — intervention group
Group type: EXPERIMENTAL
Intervention: PPN stimulation at therapeutic frequencies (20-35 Hz)
Number of subjects: 11
Study 20562469 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic PPN stimulation
Number of subjects: 11
Study 20562469 — intervention group
Group type: COMPARATOR
Intervention: PPN stimulation
Number of subjects: 11
Study 20562469 — intervention group
Group type: COMPARATOR
Intervention: Baseline performance
Number of subjects: 11
Study 18192132 — intervention group
Group type: EXPERIMENTAL
Intervention: daily‐dose blister packaging (Pill Calendar)
Number of subjects: 85
Study 18192132 — intervention group
Group type: COMPARATOR
Intervention: traditional bottles of loose tablets
Number of subjects: 85
Study 16169353 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 10994
Study 14728840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervening measures (six measures used)
Number of subjects: 1597
Study 14728840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervening measures)
Number of subjects: 1597
Study 10229296 — intervention group
Group type: EXPERIMENTAL
Intervention: Epalrestat
Number of subjects: 0
Study 10229296 — intervention group
Group type: EXPERIMENTAL
Intervention: SNK-860
Number of subjects: 0
Study 8696904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 284
Study 8696904 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 284
Study 2607269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instrumentation
Number of subjects: 50
Study 2607269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation with the Cavi‐Endo unit
Number of subjects: 50
Study 2607269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation with the Enac unit
Number of subjects: 50
Study 2607269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic instrumentation with the Medidenta unit
Number of subjects: 50
Study 2607269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic instrumentation with the Endostar 5 unit
Number of subjects: 50
Study 2607269 — intervention group
Group type: COMPARATOR
Intervention: Control (tap water)
Number of subjects: 50
Study 776090 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate cream
Number of subjects: 180
Study 776090 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide cream
Number of subjects: 180
Study 30927579 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness-based stress management program
Number of subjects: 80
Study 30927579 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation using a leaflet
Number of subjects: 80
Study 28526481 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support call (2‐10 minutes) 3 days before or 3 days after receiving an invitation letter to physiotherapy sessions
Number of subjects: 130
Study 28526481 — intervention group
Group type: COMPARATOR
Intervention: No telephone support call
Number of subjects: 130
Study 26681630 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AG)
Number of subjects: 33
Study 26681630 — intervention group
Group type: COMPARATOR
Intervention: Combined training (CG)
Number of subjects: 33
Study 22920242 — intervention group
Group type: EXPERIMENTAL
Intervention: Valgus knee brace
Number of subjects: 28
Study 22920242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedged insole
Number of subjects: 28
Study 21481265 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace physical activity intervention (3 month tool-kit of activities targeting components of the Theory of Planned Behavior)
Number of subjects: 1260
Study 21481265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1260
Study 18207228 — intervention group
Group type: EXPERIMENTAL
Intervention: ALED-I intervention (16-week program)
Number of subjects: 32
Study 18207228 — intervention group
Group type: COMPARATOR
Intervention: Delayed intent-to-treat control condition
Number of subjects: 32
Study 18207228 — intervention group
Group type: EXPERIMENTAL
Intervention: ALED-I intervention
Number of subjects: 32
Study 18207228 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 32
Study 21975580 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (500 μg/kg body weight)
Number of subjects: 24
Study 16019368 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg testosterone gel
Number of subjects: 15
Study 16019368 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg testosterone gel
Number of subjects: 15
Study 16019368 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg testosterone gel
Number of subjects: 15
Study 16019368 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline testosterone levels
Number of subjects: 15
Study 12090970 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Youth Service (CYS)
Number of subjects: 195
Study 12090970 — intervention group
Group type: COMPARATOR
Intervention: Curriculum-only condition (Control)
Number of subjects: 195
Study 12090970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of CYS
Number of subjects: 195
Study 12090970 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of CYS
Number of subjects: 195
Study 10518865 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm & Hammer Dental Care Extra Whitening
Number of subjects: 115
Study 10518865 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm & Hammer Dental Care
Number of subjects: 115
Study 10518865 — intervention group
Group type: COMPARATOR
Intervention: Crest
Number of subjects: 115
Study 8027217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ) 2 mg orally
Number of subjects: 8
Study 8027217 — intervention group
Group type: COMPARATOR
Intervention: AVP (0.0143 IU/kg BW, iv)
Number of subjects: 8
Study 2692094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg tid for 10 days)
Number of subjects: 41
Study 2692094 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (1 g tid for 10 days)
Number of subjects: 41
Study 2692094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 41
Study 2692094 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 41
Study 818040 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumapax
Number of subjects: 66
Study 818040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31522785 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine infusion (1.2 μmol kg-1 min-1)
Number of subjects: 18
Study 29666372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 16
Study 29666372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 16
Study 26473986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg
Number of subjects: 0
Study 26473986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 0
Study 24118306 — intervention group
Group type: EXPERIMENTAL
Intervention: Total atrial conduction time (TACT) assessed via tissue Doppler imaging (PA‐TDI interval) measured 6 hours after successful direct‐current electrical cardioversion (CV)
Number of subjects: 54
Study 24118306 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who maintained sinus rhythm)
Number of subjects: 54
Study 22211402 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV ablation (IPVA)
Number of subjects: 69
Study 22211402 — intervention group
Group type: COMPARATOR
Intervention: GSV ablation (GSVA)
Number of subjects: 69
Study 21103799 — intervention group
Group type: EXPERIMENTAL
Intervention: Active theater program
Number of subjects: 20
Study 21103799 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (control group)
Number of subjects: 20
Study 18502545 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 with DTaP-IPV-HBV-Hib
Number of subjects: 266
Study 18502545 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV-HBV-Hib
Number of subjects: 266
Study 16006888 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine therapy
Number of subjects: 42
Study 16006888 — intervention group
Group type: COMPARATOR
Intervention: Nilutamide (antiandrogen therapy)
Number of subjects: 42
Study 16006888 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (vaccine + nilutamide)
Number of subjects: 42
Study 16006888 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (vaccine + nilutamide) after vaccine arm progression
Number of subjects: 42
Study 12094191 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin dosing of approximately 14 U/kg/h or an aPTT of approximately 70 seconds
Number of subjects: 5335
Study 12094191 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy
Number of subjects: 5335
Study 12094191 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin dosing
Number of subjects: 5335
Study 12094191 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin resistance with high dosages and low aPTT values
Number of subjects: 5335
Study 10521156 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions designed to influence age at first intercourse and improve educational performance
Number of subjects: 0
Study 10521156 — intervention group
Group type: COMPARATOR
Intervention: Teenage mothers
Number of subjects: 0
Study 10521156 — intervention group
Group type: COMPARATOR
Intervention: Areas of the country with higher rates of teenage motherhood
Number of subjects: 0